Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$10.71
−$1.28 · -10.68%
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
Previous close
$10.71
−$1.28 · -10.68%
Pre-market
$10.56
−$0.15 · -1.40%
Sep 9, 4:00 AM ET
Regular session · ET · Market data may be delayed.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
Day range
Current $10.71
52-week range
Current $10.71
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
59
Fair Value
Sentiment
52
Mixed
Risk
74
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
Day range
Current $10.71
52-week range
Current $10.71
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 539.57M CNY | 515.82M CNY | 537.44M CNY | 563.24M CNY | 507.86M CNY |
| Cost of goods sold | 136.65M CNY | 153.42M CNY | 174.21M CNY | 183.2M CNY | 143.72M CNY |
| Gross profit | 402.91M CNY | 362.4M CNY | 363.23M CNY | 380.04M CNY | 364.15M CNY |
| Research and development | 166.49M CNY | 232.29M CNY | 347.02M CNY | 421.87M CNY | 367.86M CNY |
| Selling, general, and administrative | 291.27M CNY | 452.54M CNY | 685.53M CNY | 938.58M CNY | 793.35M CNY |
| Operating expenses | 457.76M CNY | 719.96M CNY | 1.03B CNY | 1.36B CNY | 1.16B CNY |
| Interest income | 8.05M CNY | 12.21M CNY | 17.96M CNY | 9.46M CNY | 3.46M CNY |
| Interest expense | 30K CNY | — | — | — | 1.54M CNY |
| Depreciation and amortization | 21.76M CNY | 52.2M CNY | 133.4M CNY | 124.1M CNY | 47.77M CNY |
| Operating income | −54.85M CNY | −357.56M CNY | −669.32M CNY | −980.41M CNY | −797.06M CNY |
| Net income | −55.35M CNY | −346.63M CNY | −653.69M CNY | −971.23M CNY | −796.7M CNY |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 15, 2024 | 1:10 | — | — |
Stock split | Aug 1, 2014 | 1:3 | — | — |
Effective May 15, 2024
1:10
Effective Aug 1, 2014
1:3
Funds reporting this stock among their holdings, ordered by reported position size.
Schwab International Equity ETFSCHF19.56M0.03%70.29B USD0.03%$28.47-0.38%
Schwab Fundamental International Large Company Index ETFFNDF16.8M0.06%26.49B USD0.25%$56.17-0.25%
State Street SPDR Portfolio Developed World ex-US ETFSPDW13.39M0.03%42.46B USD0.03%$52.08-0.44%
State Street SPDR Portfolio Europe ETFSPEU362.57K0.05%737.56M USD0.07%$56.45-0.58%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA274.81K0.03%1.08B USD0.30%$101-0.86%
WisdomTree International Efficient Core FundNTSI225.85K0.04%502.17M USD0.26%$48.2271-0.48%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX207.67K0.04%514.03M USD0.20%$55.545-0.73%
Invesco Golden Dragon China ETFPGJ42.63K0.05%88.04M USD0.70%$23.02-1.58%Schwab International Equity ETFSCHFSchwab Fundamental International Large Company Index ETFFNDFState Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAWisdomTree International Efficient Core FundNTSIState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXInvesco Golden Dragon China ETFPGJAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
